礼来Jaypirca联合维奈克拉限时疗法显著延长经治CLL/SLL患者无进展生存期

美股速递
Apr 13

一项最新研究数据显示,礼来公司的布鲁顿酪氨酸激酶抑制剂Jaypirca,在联合维奈克拉的限时治疗方案中,为既往接受过治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者带来了显著更优的无进展生存期。这一积极结果凸显了该联合疗法在改善患者临床结局方面的巨大潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10